2. McAlindon T.E., Bannuri R.R., Sullivan M.C. et al. OARSI guidelines for the non-surgical management of knee osteoarthritis. Osteoarthritis Cartilage. 2014;22(3):363–88. Doi: 10.1016/j. joca.2014.01.003.

3. Bruyere O., Honvo G., Veronese N., et al. An updated algorithm recommendation for the management of knee osteoarthritis from European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Semin Arthritis Rheum. 2019;49(3):337–50. Doi: 10.1016/j. semarthrit.2019.04.008.

4. Dell’Isola A., Pihl K., Turkiewicz A., et al. Risk of comorbidities following physician-diagnosed knee or hip osteoarthritis: A register-based cohort study. Arthritis Care Res (Hoboken). 2022;74(10):1689–95. Doi: 10.1002/ acr.24717.

5. Muckelt P..E., Roos E.M., Stokes M., et al. Comorbidities and their link with individual health status: A cross-sectional analysis of 23,892 people with knee and hip osteoarthritis from primary care. J Comorb. 2020;10:2235042X20920456. Doi: 10.1177/2235042X20920456.

6. Constantino de Campos G., Mundi R., Whittington C., et al. Osteoarthritis, mobility- related comorbidities and mortality: An overview of meta-analyses. Ther Adv Musculoskelet Dis. 2020;12:1759720X20981219. Doi: 10.1177/1759720X20981219.

7. Лила А.М., Алексеева Л.И., Телышев К.А. Современные подходы к фенотипированию остеоартрита. Современная ревматология. 2019;13(2):4–8. [Lyla A.M., Alekseeva L.I., Telyshev K.A. Modern approaches to phenotyping of osteoarthritis. Sovremennaya rhevmatologiya. 2019;13(2):4–8. (In Russ.) Doi: 10.14412/1996-7012-2019-2-4-8.

8. Simental-Mendia M., Sanchez-Garcia A., Vilchez-Cavazos F., et al. Effect of glucosamine and chondroitin sulfate in symptomatic knee osteoarthritis: a systematic review and meta-analysis of randomized placebo- controlled trials. Rheum Int. 2018 38(8):1413–28. Doi: 10.1007/s00296-018- 4077-2.

9. Navarro S.L., White E., Kantor et al. Randomizedtrial of glucosamine and chondroitin supplementation on inflammation and oxidative stress biomarkers and plasma proteomics profiles in healthy humans. PLoS One, 2015;10(2):e0117534. Doi: 10.1371/journal.pone.0117534.

10. Navarro S.L., Herrero M., Martinez H., et al. Differences in Serum Biomarkers Between Combined Glucosamine and Chondroitin Versus Celecoxib in a Randomized, Double-blind Trial in Osteoarthritis Patients. Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry. 2020;19(2):190–201. Doi: 10.2174/1871523 018666190115094512.

11. King D.E., Xiang J. Glucosamine/chondroitin and mortality in US NHAHES cohort. J Am Board Fam Med. 2020;33(6):842–47. Doi: 10.3122/ jabfm.2020.06.200110.

12. Khan A., Mannan Vij., Pervaiz M.A., et al. The Role of Glucosamine and Chondroitin Sulfate in the Prevention of Colorectal Cancer: A Systematic Review. Cureus. 2022;14(5):e25401. Doi: 10.7759/cureus.25401.

13. Henrotin Y., Lambert C., Richette P. Importance of synovitis in osteoarthritis: evidence for the use of glycosaminoglycansagainstsynovialinflammation. Semin Arthritis Rheum. 2014;43(5):579–87. Doi: 10.1016/j.semarthrit.2013.10/005.

14. Fransen M., Agaliotis M., Nair L., et al. Glucosamine and chondroitin for knee osteoarthritis: a double-blind randomised placebo-controlled clinical trial evaluating single and combination regimens. Ann Rheum Dis. 2015;74(5): 851–58. Doi: 10.1136/annrheumdis-2013- 203954.

15. Yang W., Sun C., He S.Q., et al. The efficacy and safety of disease-modifying osteoarthritis drugs for knee and hip osteoarthritis – A systematic review and network meta-analysis. J Gen Intern Med. 2021;36(7):2085–93. Doi: 10.1007/ s11606-021-06755-z.

16. Алексеева Л.И., Шарапова Е.П., Кашеварова Н.Г., Таскина Е.А., Аникин С.Г., Лила А.М., Мендель О.И. Многоцентровое проспективное наблюдательное исследование по применению препаратов АРТРА МСМ Форте и АРТРА у пациентов с остеоартритом коленных и/ или тазобедренных суставов и/или с болью в нижней части спины (предварительные результаты). Трудный пациент. 2018;16:34-41.